IFP Advisors’s Cytek Biosciences CTKB Stock Holding History

IFP Advisors’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.65K	Sell	597 -389	-39%	-$1.66K	﹤0.01%	4105
2026 Q1	$4.31K	Buy	986 +276	+39%	+$1.3K	﹤0.01%	3612
2025 Q4	$3.59K	Hold	710	–	–	﹤0.01%	3587
2025 Q3	$2.46K	Buy	710 +102	+17%	+$383	﹤0.01%	3612
2025 Q2	$2.6K	Buy	+608	New	+$2.03K	﹤0.01%	3774
2025 Q1	–	Hold	0	–	–	–	4191
2024 Q4	–	Hold	0	–	–	–	4412
2023 Q1	–	Sell	-480	Closed	-$8K	–	3578
2022 Q4	$8K	Buy	+480	New	+$6.45K	﹤0.01%	3498

Other funds holding CTKB

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

LSERS

Louisiana State Employees Retirement System Baton Rouge, Louisiana $5.7B AUM 35.76% 1-Year Est. Return

NAM

NorthCrest Asset Manangement Plymouth, Minnesota $3.89B AUM 40.33% 1-Year Est. Return

EFG

Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

IFP Advisors's CTKB Position: Q2 2026 in Review

IFP Advisors reduced its Cytek Biosciences (CTKB) stake by 39% in Q2 2026, selling an estimated $1.66K and leaving 597 shares worth $2.65K. The position accounts for ﹤0.01% of the portfolio, ranked #4105.

IFP Advisors first reported a position in CTKB in Q4 2022 and has held it in 6 quarters since. The position peaked at $8K in Q4 2022. 14 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

IFP Advisors held 597 shares of Cytek Biosciences worth $2.65K as of Q2 2026.
IFP Advisors sold 389 Cytek Biosciences shares in Q2 2026, an estimated $1.66K.
Cytek Biosciences made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #4105 holding.
IFP Advisors first reported a position in Cytek Biosciences in Q4 2022 and has held it in 6 quarters since.
IFP Advisors's Cytek Biosciences position peaked at $8K in Q4 2022.
14 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.